Aap Implantate AG Announces Capital Increase with Exclusion of Subscription Rights

aap Implantate AG has officially declared an increase in the company's share capital through the issuance of new no-par value bearer shares. This strategic move, approved by both the Management and Supervisory Boards, excludes shareholders' subscription rights and aims to enhance the equity base of the company. The capital increase involves issuing 896,647 new shares, thus raising the share capital from EUR 8,966,474.00 to EUR 9,863,121.00.

The announcement specifies that each new share has a pro-rata amount of the share capital equal to EUR 1.00 and will be offered at an issue price of EUR 1.10. This capital boost corresponds to almost 10% of the existing share capital and takes effect from January 1, 2024, with the new shares carrying dividend rights from the onset. The transaction is set to proceed via a private placement to a selected investor, bringing the gross issue proceeds to approximately EUR 986,311.70.

This financial maneuver is designed to fortify the company's equity base, thereby facilitating its ongoing and future projects. aap Implantate AG remains focused on advancing medical technology, particularly in the field of traumatology, via the marketing of innovative products and the development of future projects such as antibacterial silver coating technology and magnesium-based implants.